ABT Abbott Laboratories
Healthcare$86.67-0.85%ClosedMarket Cap: $150.95B
As of 2026-05-26
Valuation
P/E (TTM)
26.72
PEG
—
P/B
2.93
P/S
3.37
EV/EBITDA
16.61
DCF Value
$143.01
FCF Yield
4.8%
Div Yield
2.8%
Margins & Returns
Gross Margin
56.4%
Operating Margin
18.2%
Net Margin
13.9%
ROE
12.2%
ROA
5.7%
ROIC
6.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $11.16B | 56.3% | $1.84B | $1.08B | $— | $0.63 |
| Q4 null | $11.46B | 57.0% | $2.25B | $1.78B | $— | $0.59 |
| FY null | $44.33B | 55.5% | $8.05B | $6.52B | $— | $2.36 |
| Q3 null | $11.37B | 55.7% | $2.06B | $1.64B | $— | $0.59 |
| Q2 null | $11.14B | 56.4% | $2.05B | $1.78B | $— | $0.59 |
| Q1 null | $10.36B | 52.6% | $1.69B | $1.32B | $— | $0.59 |
| Q4 null | $10.97B | 51.0% | $1.99B | $9.23B | $— | $0.55 |
| FY null | $41.95B | 50.8% | $6.83B | $13.40B | $— | $2.20 |
| Q3 null | $10.63B | 51.0% | $1.82B | $1.65B | $— | $0.55 |
| Q2 null | $10.38B | 51.1% | $1.69B | $1.30B | $— | $0.55 |
| Q1 2024 | $9.96B | 50.4% | $1.39B | $1.23B | $0.70 | $0.55 |
| Q4 2023 | $10.24B | 51.3% | $1.86B | $1.59B | $0.91 | $0.51 |